This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on ISI (27)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Neurology, Other  • Alert me on articles by topic

William M. Pardridge, MD

Arch Neurol. 2002;59:35-40.

The blood-brain barrier (BBB) is maintained by the endothelial tight junctions within the brain microvasculature. Most small-molecule neuropharmaceutical agents and virtually all large-molecule drugs do not cross the BBB. The BBB problem is the rate-limiting factor preventing the transfer of progress in the molecular neurosciences to the development of clinically effective neurotherapeutic agents. The future development of neurotherapeutic agents will be accelerated by the development of BBB drug-targeting technology.

From the Department of Medicine, University of California, Los Angeles, UCLA School of Medicine.

RELATED ARTICLE

Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2002;59(1):155-157.
FULL TEXT